A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Pexidartinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company; Plexxikon
- 08 Apr 2024 Planned End Date changed from 1 Mar 2024 to 31 Mar 2025.
- 08 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 16 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2023.